

Mariaelena Capone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3042728/publications.pdf>

Version: 2024-02-01

59
papers

2,865
citations

279798

23
h-index

233421

45
g-index

61
all docs

61
docs citations

61
times ranked

5371
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	7.0	459
2	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	1.6	419
3	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
4	Main roads to melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 86.	4.4	157
5	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	7.0	146
6	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 54.	4.4	104
7	miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5005-13.	7.1	99
8	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1387706.	4.6	76
9	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244.	4.4	73
10	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008842.	4.6	72
11	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	3.4	61
12	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
13	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Oncolmmunology</i> , 2017, 6, e1261242.	4.6	59
14	Proportions of blood-borne V β 1+ and V β 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016, 64, 116-126.	2.8	54
15	Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. <i>Cancer Immunology Research</i> , 2019, 7, 841-852.	3.4	47
16	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1405206.	4.6	43
17	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Scientific Reports</i> , 2019, 9, 7449.	3.3	43
18	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon- γ 2b treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 76.	4.4	39

#	ARTICLE	IF	CITATIONS
19	Characterization of a Novel Polymorphism in PPARC Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-7.	3.0	36
20	Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. , 2022, 10, e004043.		34
21	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
22	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	4.4	31
23	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009, 274, 331-336.	7.2	30
24	Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. <i>Journal of Translational Medicine</i> , 2020, 18, 121.	4.4	29
25	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
26	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	4.4	24
27	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
28	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers</i> , 2019, 11, 1425.	3.7	22
29	Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1801.	4.1	20
30	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011, 25, 1495-502.	2.6	19
31	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>Journal of Translational Medicine</i> , 2015, 13, 37.	4.4	15
32	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
33	Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies. <i>Cancer Letters</i> , 2015, 357, 286-296.	7.2	11
34	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
35	The Ratio of GrzB+ $\hat{\sim}$ FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 2325.	3.7	7
36	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021, 19, 17.	4.4	6

#	ARTICLE	IF	CITATIONS
37	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 811131.	4.8	6
38	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. <i>Cancers</i> , 2021, 13, 4164.	3.7	5
39	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2022, 12, 5448.	3.3	5
40	Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytesâ€™ iTNF-Î± Expression. <i>Biology</i> , 2021, 10, 735.	2.8	4
41	Enzyme activity of circulating CD73 in human serum. <i>Methods in Enzymology</i> , 2019, 629, 257-267.	1.0	3
42	Mutation frequency in <i>BRAF</i> and <i>NRAS</i> genes among primary tumors and different types of metastasis from melanoma patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8574-8574.	1.6	3
43	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	2
44	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, O8.	4.4	2
45	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	4.4	2
46	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. <i>Methods in Enzymology</i> , 2020, 635, 21-31.	1.0	2
47	Abstract 558: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma. , 2018, , .		2
48	Abstract 3677: Pattern and distribution of BRAF/NRAS and P16CDKN2A mutations among primary and secondary lesions in melanoma patients. , 2012, , .		2
49	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. , 2013, 1, .		1
50	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. <i>Journal of Translational Medicine</i> , 2014, 12, O13.	4.4	1
51	Immunoscore as new possible approach for the classification of melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20020-e20020.	1.6	1
52	9320 Treatment with intravenous High Dose Interferon (HDI) is able to reduce levels of circulating regulatory T (Treg) cells in melanoma patients. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 583.	2.2	0
53	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
54	CD73 activity and outcome of advanced melanoma patients treated with nivolumab. <i>European Journal of Cancer</i> , 2018, 92, S22.	2.8	0

#	ARTICLE	IF	CITATIONS
55	Identification of potential predictive biomarkers of rapid progression and rapid response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients.. Journal of Clinical Oncology, 2020, 38, e22068-e22068.	1.6	0
56	Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.. Journal of Clinical Oncology, 2020, 38, e22008-e22008.	1.6	0
57	Abstract 5529: Proteomic profiling of FFPE tumors samples from melanoma subjects treated with anti-PD-1 immunotherapy identifies proteins associated with response to treatment. , 2020, , .		0
58	761â€¦Potential predictive biomarkers of rapid progression and response to anti-PD1 treatment by gene profiling analysis in metastatic melanoma patients. , 2020, , .		0
59	229â€¦Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy. , 2020, , .		0